Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

As it embarks on a widespread effort to remind users of the proper care and keeping of the hand-held readers used with its FreeStyle Libre continuous glucose monitors, Abbott is further expanding the ...

A manufacturing problem in millions of Abbott glucose sensors has been tied to at least seven deaths and hundreds of injuries worldwide.

Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warning they could produce ...

Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...